Latest News & Updates
Breaking News
39 minutes ago
Pharma Now Editorial Team
Pharma Now Editorial Team
Pharma Now Editorial Team
Other trending news you may like to read
Karyopharm Achieves Full Enrollment in Phase 3 Endometrial Cancer Trial with Topline Data Due Mid-2026
Karyopharm completes Phase 3 XPORT-EC-042 enrollment; mid-2026 topline data could trigger selinexor sNDA and manufacturing scale-up decisions.
Pharma Now Editorial Team
Ipsen Unveils Corabotase as First-in-Class Recombinant Neuroinhibitor at SCALE 2026 Symposium
Ipsen presents corabotase Phase II data at SCALE 2026, introducing the first recombinant neuroinhibitor class with distinct biologics manufacturing and regulatory implications.
Pharma Now Editorial Team
Cellectar Biosciences Secures $140 Million Financing to Advance Iopofosine I 131 Toward FDA Accelerated Approval in Rare Lymphoma
Cellectar closes $140M financing to fund iopofosine I 131 Phase 3 confirmatory study and FDA accelerated approval filing in r/r Waldenström Macroglobulinemia.
Pharma Now Editorial Team
Cognition Therapeutics Secures Second Philanthropic Donation to Extend Zervimesine Expanded Access Program in DLB
A second philanthropic donation extends Cognition Therapeutics' zervimesine EAP in DLB to two years as an FDA registrational meeting approaches in Q2 2026.
Pharma Now Editorial Team
